세계의 난포 자극 호르몬 시장 예측(-2032년) : 제품 유형, 투여 경로, 유통 채널, 용도, 최종 사용자, 지역별 분석

According to Stratistics MRC, the Global Follicle stimulating Hormone Market is accounted for $2.6 billion in 2025 and is expected to reach $3.9 billion by 2032 growing at a CAGR of 6% during the forecast period. Follicle Stimulating Hormone (FSH) is a glycoprotein hormone produced by the anterior pituitary gland. It plays a crucial role in reproductive health by regulating the growth, development, and function of the ovaries in females and the testes in males. In women, it stimulates ovarian follicle maturation; in men, it promotes spermatogenesis. FSH levels are often measured to assess fertility, menstrual irregularities, or pituitary function.

According to the World Health Organization (WHO) data updated in April 2023, approximately 1 in 6 adults globally are affected by infertility.

Market Dynamics:

Driver:

Growing awareness and acceptance of fertility treatments

Increasing infertility rates globally, coupled with enhanced knowledge about advanced reproductive technologies such as IVF, have led to a rising demand for effective fertility solutions. Additionally, expanding healthcare infrastructure, including fertility clinics and specialized centers, supports greater accessibility to FSH therapies. This awareness encourages more patients to seek treatment, driving market growth. Furthermore, technological advancements in FSH production and delivery methods improve treatment outcomes, reinforcing market expansion.

Restraint:

Adverse effects and safety concerns

Adverse effects and safety concerns related to FSH treatments pose challenges to market growth. Some patients experience side effects such as ovarian hyperstimulation syndrome (OHSS), allergic reactions, or hormonal imbalances, which can deter treatment adoption. Moreover, the high cost of fertility treatments, including FSH therapies, restricts access, especially in low-income regions lacking insurance coverage. These safety and financial concerns limit patient willingness and ability to pursue FSH-based fertility interventions, thereby restraining overall market expansion.

Opportunity:

Product innovation and biosimilars

Recombinant FSH products, developed through advanced recombinant DNA technology, provide higher purity and consistency compared to urinary-derived hormones, enhancing efficacy and safety. The emergence of biosimilars can reduce treatment costs, making fertility care more affordable and accessible to a broader population. Additionally, innovations in drug delivery systems, such as pre-filled syringes and pen injectors, improve patient convenience and compliance, further stimulating market growth.

Threat:

Ethical and religious concerns

Ethical and religious concerns present significant threats to the FSH market. Assisted reproductive technologies (ART), including the use of FSH, often face scrutiny related to embryo manipulation, storage, and genetic testing, raising moral and cultural debates. These concerns can influence public perception and lead to restrictive regulatory policies in certain regions, limiting market penetration.

Covid-19 Impact:

The COVID-19 pandemic disrupted the FSH market primarily through the suspension of non-urgent fertility treatments, including IVF, causing delays averaging nearly two months in many countries. Travel restrictions also limited patient access to fertility clinics, especially for medical tourism. Psychological stress during the pandemic further affected fertility outcomes. Additionally, supply chain interruptions delayed medication availability. However, clinics adapted by implementing safety protocols and offering remote counseling, leading to a gradual recovery in demand as restrictions eased and treatments resumed.

The recombinant FSH segment is expected to be the largest during the forecast period

The recombinant FSH segment is expected to account for the largest market share during the forecast period due to its superior purity, consistency, and bioactivity, achieved through recombinant DNA technology in genetically engineered cell lines. This method minimizes impurities found in urinary-derived FSH, enhancing safety and treatment efficacy. The segment's growth is further supported by increasing adoption of assisted reproductive technologies and infertility treatments worldwide. Moreover, ongoing research and development efforts continue to improve recombinant FSH formulations, solidifying its position as the preferred choice in fertility therapies and contributing to its largest market share.

The injectable segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the injectable segment is predicted to witness the highest growth rate, driven by their widespread use in fertility treatments such as ovarian stimulation. Injectables provide precise dosing and rapid bioavailability, which are critical for effective therapy. Additionally, advancements in injection devices, including pen injectors and pre-filled syringes, enhance patient convenience and compliance. The growing preference for injectable forms over other delivery methods, combined with rising infertility rates and expanding ART adoption, fuels this segment's rapid market growth.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share owing to its advanced healthcare infrastructure, high awareness of infertility and fertility treatments, and favorable reimbursement policies for assisted reproductive technologies. The region benefits from significant investments in biotechnology and pharmaceutical research, resulting in early adoption of innovative FSH therapies. Moreover, a high prevalence of infertility, coupled with a growing number of fertility clinics and specialized centers, drives robust demand.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR due to increasing infertility rates, rising disposable incomes, and expanding healthcare infrastructure. Growing awareness and acceptance of fertility treatments, along with government initiatives to improve reproductive health, contribute to rising demand. The region's expanding middle class and improvements in assisted reproductive technologies further accelerate market adoption.

Key players in the market

Some of the key players in Follicle stimulating Hormone Market include Ferring Pharmaceuticals, Merck KGaA, Pfizer Inc., Teva Pharmaceutical Industries Ltd., Allergan plc, Ipsen Pharma, LG Chem Ltd., Asarina Pharma, Intas Pharmaceuticals Ltd., Bharat Serums and Vaccines Ltd., Sun Pharmaceutical Industries Ltd., Gedeon Richter Plc., Sandoz International GmbH, BioTech Pharmacal, Fuji Pharma Co., Ltd., Lupin Limited, Geneo Pharma, and Fidia Farmaceutici S.p.A.

Key Developments:

In May 2024, The National Medical Products Administration (NMPA) in China approved Rekovelle(R), with a commercial launch planned for 2025.

In January 2020, Merck announced that the European Commission had granted Marketing Authorization for a new GONAL-f(R) (follitropin alfa) 150 IU pen. GONAL-f(R) is a recombinant human follicle-stimulating hormone (r-hFSH) used to treat anovulation and to stimulate the development of multiple follicles in women undergoing assisted reproductive technologies (ART).

Product Types Covered:

• Recombinant FSH
• Urinary FSH (uFSH)

Route of Administrations Covered:

• Injectable
• Other Routes

Distribution Channels Covered:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Specialty Drug Stores

Applications Covered:

• Assisted Reproductive Technology (ART)
• Hypogonadism
• Ovulation Induction
• Other Applications

End Users Covered:

• Hospitals
• Fertility Clinics/Infertility Centers
• Research Institutes & Academic Centers
• Other End Users

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Product Analysis
• 3.7 Application Analysis
• 3.8 End User Analysis
• 3.9 Emerging Markets
• 3.10 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Follicle stimulating Hormone Market, By Product Type

• 5.1 Introduction
• 5.2 Recombinant FSH
  • 5.2.1 Pure Recombinant FSH
  • 5.2.2 Mixed Recombinant FSH Formulations
• 5.3 Urinary FSH (uFSH)

6 Global Follicle stimulating Hormone Market, By Route of Administration

• 6.1 Introduction
• 6.2 Injectable
• 6.3 Other Routes

7 Global Follicle stimulating Hormone Market, By Distribution Channel

• 7.1 Introduction
• 7.2 Hospital Pharmacies
• 7.3 Retail Pharmacies
• 7.4 Online Pharmacies
• 7.5 Specialty Drug Stores

8 Global Follicle stimulating Hormone Market, By Application

• 8.1 Introduction
• 8.2 Assisted Reproductive Technology (ART)
  • 8.2.1 In Vitro Fertilization (IVF)
  • 8.2.2 Intracytoplasmic Sperm Injection (ICSI)
• 8.3 Hypogonadism
• 8.4 Ovulation Induction
• 8.5 Other Applications

9 Global Follicle stimulating Hormone Market, By End User

• 9.1 Introduction
• 9.2 Hospitals
• 9.3 Fertility Clinics/Infertility Centers
• 9.4 Research Institutes & Academic Centers
• 9.5 Other End Users

10 Global Follicle stimulating Hormone Market, By Geography

• 10.1 Introduction
• 10.2 North America
  • 10.2.1 US
  • 10.2.2 Canada
  • 10.2.3 Mexico
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 UK
  • 10.3.3 Italy
  • 10.3.4 France
  • 10.3.5 Spain
  • 10.3.6 Rest of Europe
• 10.4 Asia Pacific
  • 10.4.1 Japan
  • 10.4.2 China
  • 10.4.3 India
  • 10.4.4 Australia
  • 10.4.5 New Zealand
  • 10.4.6 South Korea
  • 10.4.7 Rest of Asia Pacific
• 10.5 South America
  • 10.5.1 Argentina
  • 10.5.2 Brazil
  • 10.5.3 Chile
  • 10.5.4 Rest of South America
• 10.6 Middle East & Africa
  • 10.6.1 Saudi Arabia
  • 10.6.2 UAE
  • 10.6.3 Qatar
  • 10.6.4 South Africa
  • 10.6.5 Rest of Middle East & Africa

11 Key Developments

• 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 11.2 Acquisitions & Mergers
• 11.3 New Product Launch
• 11.4 Expansions
• 11.5 Other Key Strategies

12 Company Profiling

• 12.1 Ferring Pharmaceuticals
• 12.2 Merck KGaA
• 12.3 Pfizer Inc.
• 12.4 Teva Pharmaceutical Industries Ltd.
• 12.5 Allergan plc
• 12.6 Ipsen Pharma
• 12.7 LG Chem Ltd.
• 12.8 Asarina Pharma
• 12.9 Intas Pharmaceuticals Ltd.
• 12.10 Bharat Serums and Vaccines Ltd.
• 12.11 Sun Pharmaceutical Industries Ltd.
• 12.12 Gedeon Richter Plc.
• 12.13 Sandoz International GmbH
• 12.14 BioTech Pharmacal
• 12.15 Fuji Pharma Co., Ltd.
• 12.16 Lupin Limited
• 12.17 Geneo Pharma
• 12.18 Fidia Farmaceutici S.p.A.